Lam Ching, van Velthoven Michelle Helena, Meinert Edward
Digitally Enabled PrevenTative Health Research Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Department of Primary Care and Public Health, Imperial College London, London, United Kingdom.
JMIR Res Protoc. 2020 Mar 31;9(3):e16935. doi: 10.2196/16935.
Internet of Things (IoT), or Industry 4.0, represents a smart shift to more interconnected manufacturing processes where individual entities within the supply chain communicate with each other to achieve greater flexibility and responsiveness in general manufacturing and leaner manufacturing to reduce the cost of production. IoT has become instrumental in driving leaner manufacturing and more efficient systems in other industries such as transportation and logistics. Cell-based therapeutic products could potentially transform various diseases; however, the delivery of these products is complex and challenging.
This study aims to understand the applicability of IoT in cell-based product supply chains and delivery.
We will search Medline, EMBASE (OvidSP), Web of Science, Cochrane Library & HEED, Scopus, ACM digital library, INSPEC, ScienceDirect, and the IEEE Xplore Digital Library for studies published after 2008 using a combination of keywords and subject headings related to IoT used in cell therapies. Additionally, a Google search to identify gray literature will be conducted. Two authors will independently screen the titles and abstracts identified from the search and accept or reject the studies according to the study inclusion criteria. Any discrepancies will then be discussed and resolved. The quality of the selected literature will be assessed using the Critical Appraisal Skills Programme systematic review checklist.
Data from eligible publications will be abstracted into a predesigned form to map the current and future directions of the technologies, applications, benefits, and challenges in the implementation of IoT in regenerative medicine. This study will be published in a peer-reviewed journal in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. This systematic review will be executed by June 2020, and the completed review will be published in a peer-reviewed journal to inform future developments in IoT application for the delivery of cell-based therapies.
This review paper will provide an overview of all technologies available in the area and inspect the current IoT applications in cell-based therapies to identify the benefits, challenges, and future directions of using IoT to allow safe and cost-effective delivery of cell-based therapies.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/16935.
物联网（IoT），即工业4.0，代表着向更具互联性的制造流程的智能转变，供应链中的各个实体相互通信，以在一般制造中实现更大的灵活性和响应能力，并实现更精益的制造，从而降低生产成本。物联网在推动运输和物流等其他行业实现更精益的制造和更高效的系统方面发挥了重要作用。基于细胞的治疗产品有可能改变各种疾病；然而，这些产品的交付复杂且具有挑战性。
本研究旨在了解物联网在基于细胞的产品供应链和交付中的适用性。
我们将检索Medline、EMBASE（OvidSP）、科学引文索引、考克兰图书馆及HEED、Scopus、美国计算机协会数字图书馆、INSPEC、ScienceDirect和IEEE Xplore数字图书馆，以查找2008年以后发表的使用与细胞疗法中物联网相关的关键词和主题词组合的研究。此外，还将进行谷歌搜索以识别灰色文献。两位作者将独立筛选从搜索中识别出的标题和摘要，并根据研究纳入标准接受或拒绝这些研究。然后将讨论并解决任何差异。将使用关键评估技能计划系统评价清单评估所选文献的质量。
符合条件的出版物的数据将被提取到预先设计的表格中，以描绘物联网在再生医学实施中的技术、应用、益处和挑战的当前及未来方向。本研究将根据系统评价和荟萃分析的首选报告项目指南发表在同行评审期刊上。本系统评价将于2020年6月执行，完成的评价将发表在同行评审期刊上，为基于细胞疗法的物联网应用的未来发展提供信息。
本综述论文将概述该领域现有的所有技术，并检查物联网在基于细胞的疗法中的当前应用，以确定使用物联网实现基于细胞疗法的安全且经济高效交付的益处、挑战和未来方向。
国际注册报告识别号（IRRID）：PRR1-10.2196/16935。
